Tag Archives: USPTO

Myriad Revisited – The Consequences of Prometheus Unbound

In my last post on Prometheus, I concluded: It is hard to think of a diagnostic assay claim that does not either detect the +/- presence of a marker (like anti-HIV antibodies) or involve the comparison of the level of … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , | Leave a comment

A “Modest Proposal” For The RCE Crisis

Commentators, including Prof. Hal Wegner, have been sounding the alarm regarding the increasing number of requests for continuing examination that applicants are filing. The PTO projects 325,000 RCE’s by FY 2018. They have gone further in recent posts, in attributing … Continue reading

Posted in AIA Patent Reform, USPTO Practice and Policy | Tagged , , , , , , , , , , , | Leave a comment

PTO Proposes Supplemental Examination Rules – Extremely Expensive and Incredibly Complex

On January 25, 2012, the USPTO published proposed rules to implement the supplemental examination provisions of the America Invents Act (“AIA”). This procedure is intended to be utilized by patent owners to “clean up” patents of iffy validity before, say, … Continue reading

Posted in AIA Patent Reform | Tagged , , , , , | Leave a comment

Top 2011 IP Stories on Patents4Life

I spent a day or two looking back over the breaking IP news that resulted in posts on Patents4Life. I wrote most of them, but want to take a pause to thank regular contributors Paul Cole, Ron Schutz and Stefan … Continue reading

Posted in Miscellaneous | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment